Searchable abstracts of presentations at key conferences in endocrinology

ea0056p679 | Paediatric endocrinology | ECE2018

Non-classical congenital adrenal hyperplasia: the most frequent mutations

Hayon Maria , del Carmen Serrano Maria , Blanquez David , Maria Gomez Jose , Torres Elena

Background and Objective: Congenital adrenal hyperplasia (CAH) is one of the most common diseases in pediatric endocrinology. Non-classical (NC-CAH) forms are characterized by milder enzyme dysfunction and manifests commonly in adolescence or adulthood. The most frequent form of NC-CAH occurs due to 21-hydroxylase deficiency which is caused by defects in the CYP21A2 gene. Our aim was to describe the most common 21-hydroxylase gene (CYP21A2) mutations in our geographical area i...

ea0056p966 | Male Reproduction | ECE2018

Effects of cross-sex hormone treatment on body composition in transgender persons

Hayon Maria , Blanquez David , Serrano Maria del Carmen , Aviles Maria Dolores , Torres Elena

Background: Cross-sex hormone treatments are used to masculinize or feminize the bodies of female-to-male (FtM) or male-to-female (MtF) transsexuals, respectively. Redistribution of fat mass is expected to occur during the first 1–6 months in transgender males and in the first 3–12 months in transgender females.Objective: To examine the effects of cross-gender sex hormone therapy (CHT) on body composition in transsexual men and women.<p cla...

ea0056p975 | Male Reproduction | ECE2018

Prolactin concentration in male-to-female transsexual subjects following cross-sex hormone therapy

Hayon Maria , Blanquez David , del Carmen Serrano Maria , Aviles Maria Dolores , Torres Elena

Background: Male-to-female transsexual persons use estrogens + antiandrogens to adapt their physical bodies to the female sex.Estrogens are powerful stimulators of synthesis and release of prolactin and serum prolactin levels are usually somewhat increased following estrogen treatment.Objective: To determine prolactin levels and to assess the risk of development of prolactinoma in male-to-female transgender subjects following cross-sex hormone therapy (C...

ea0049gp111 | Diabetes therapy &amp; complications 2 | ECE2017

Hepatic effects of GLP-1 receptor agonist Liraglutide in patients with type 2 diabetes

Hayon Maria , Fernandez Marta , Maraver Silvia , Muros Teresa , Cepero Daniel , Lopez Martin , Quesada Miguel , Pechuan Joaquin , Piedrola Gonzalo

Introduction: The aim of this study was to analyze the effects of Liraglutide in hepatic steatosis as well as clinical and biochemical data before and after 6 months.Methods: We have retrospectively analysed epidemiological, anthropometric and laboratory data of 83 type 2 diabetic patients treated with Liraglutide and followed at different endocrinology units across east Andalusia. We have evaluated nonalcoholic fatty liver disease using liver enzymes an...

ea0056p288 | Bone &amp; Osteoporosis | ECE2018

Fragility index in type 2 diabetes for identification of patients with risk of osteoporotic fracture or prevalent fracture

Garcia-Martin Antonia , Dolores Aviles-Perez Maria , Garcia-Fontana Beatriz , Marquez-Herandez Maria Teresa , Hayon Maria , Munoz-Torres Manuel

Introduction: Diabetes mellitus is associated with an increased risk of osteoporotic fractures, which leads to an increased risk of disability and frailty.Aims: To assess the prevalence of frailty in type 2 diabetes and to analyze the relationship with bone mineral density (BMD) and Trabecular Bone Score (TBS), fracture risk and prevalent fractures.Methods: We carried out a cross-sectional study of 75 diabetic patients (65±7 y...

ea0056p509 | Diabetes therapy | ECE2018

Addition of sodium-glucose co-transporter type 2 inhibitors to diabetic patients type 2 in treatment with glucagon-like peptide-1 agonists: clinical results

Laguna Ma del Carmen Serrano , Ponce Maria Hayon , Martinez David Blanquez , Perez Maria Dolores Aviles , Vela Elena Torres

Background: The complex involvement of multiple metabolic defects in the pathogenesis of type 2 diabetes mellitus (T2DM) makes difficult the treatment in monotherapy, therefore, the use of different antidiabetic drugs with different and complementary mechanisms of action could result in better glycemic control with favorable metabolic changes.Objective: To determine the effectiveness and safety of the addition of a sodium-glucose co-transporter type 2 in...

ea0056p907 | Endocrine Disruptors | ECE2018

Cross hormone therapy in transgender individuals: changes in lipid profile and other cardiovascular risk factor

Laguna Ma del Carmen Serrano , Ponce Maria Hayon , Martinez David Blanquez , Perez Maria Dolores Aviles , Vela Elena Torres

Background: Cross-sex hormone therapy (CHT) is known to lead to alterations in cardiovascular risk factor(CVRF).Objective: To assess changes in lipid profile and other CVRF in transsexual subjects receiving CHT.Materials and methods: Retrospective longitudinal study. We evaluated individuals with gender identity disorder following CHT, assisted in the Gender Identity Unit from 2015 to 2017. Primary endpoint was lipid profile change...

ea0063p923 | Diabetes, Obesity and Metabolism 3 | ECE2019

Flash glucose monitoring system in children under 18 years old with diabetes mellitus type 1 in the southern hospital area of Granada: preliminary results

Utrero Sara Leon , Ponce Maria Hayon , Laguna Ma Del Carmen Serrano , Torres Elena Lopez-Mezquita , Charneco Miguel Quesada , Vela Elena Torres

Objective: To evaluate the baseline characteristics and their evolution three months after implantation of the Flash glucose monitoring System (Freestyle Libre), after financing by the Andalusian Health Service in patients under 18 years old with type 1 diabetes mellitus (DM1) in our hospital area.Material and Methods: A descriptive observational and retrospective study that includes patients with DM1 under 18 years old from the southern hospital area of...

ea0063p974 | Diabetes, Obesity and Metabolism 3 | ECE2019

Canagliflozin: Ankle-Brachial index (ABPI) and risk of amputations

Laguna Ma del Carmen Serrano , Ponce Maria Hayon , Utrero Sara Leon , Perez Luisa Sebastian , Torres Enrique Redondo , Charneco Miguel Quesada , Vela Elena Torres

Objectives: Assess the canagliflozin effect on the ABPI in patients without previous treatment with iSGLT-2 as a possible etiology of tissue hypoperfusion and a risk factor for amputations.Material and methods: Prospective observational study where we analyzed patients diagnosed of type 2 diabetes mellitus (DM2) with poor metabolic control and without prior treatment with iSGLT-2, which is initiated treatment with canagliflozin. Clinical, biochemical par...

ea0049ep581 | Diabetes therapy | ECE2017

The role of sodium-glucose co-transporter 2 inhibitors as add-on therapy in type 2 diabetes

Ponce Maria Hayon , Blanquez Martinez David , Jimenez Maria Jose Jimenez , Cordova Rossana Sofia Manzanares , Laguna Maria del Carmen Serrano , Charneco Miguel Quesada , Casares Martin Lopez de la Torre

Objective: SGLT2 inhibitors, have been shown to improve glycaemic control, stabilize insulin dosing and mitigate insulin-associated weight gain in patients whose type 2 diabetes mellitus (T2DM) was inadequately controlled. The objective is to evaluate the real-world efficacy and safety of adding iSGLT-2 therapy in inadequately controlled patients with oral antidiabetic drugs and with or without insulin therapy.Materials and methods: This observational st...